Answer
Rash, headache, pyrexia (fever) and respiratory tract infections occurred in at least 20% of patients receiving Lemtrada (alemtuzumab) in multiple sclerosis clinical studies.
Sources for this answer
- LEMTRADA 12 mg concentrate for solution for infusionSANOFI · emc · SmPC §4.8 Undesirable effects · Version 3Document updated
Sources checked